These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 15474237

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations.
    Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C.
    Reprod Toxicol; 2008 Sep; 26(1):36-41. PubMed ID: 18588969
    [Abstract] [Full Text] [Related]

  • 5. Paternal exposure and counselling: experience of a Teratology Information Service.
    De Santis M, Cesari E, Cavaliere A, Ligato MS, Nobili E, Visconti D, Caruso A.
    Reprod Toxicol; 2008 Sep; 26(1):42-6. PubMed ID: 18598753
    [Abstract] [Full Text] [Related]

  • 6. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools.
    Uhl K, Trontell A, Kennedy D.
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):337-48. PubMed ID: 16953517
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Continued occurrence of Accutane-exposed pregnancies.
    Honein MA, Paulozzi LJ, Erickson JD.
    Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
    [Abstract] [Full Text] [Related]

  • 12. Risk assessment of drug use in pregnancy: prevention of birth defects.
    Peters PW.
    Ann Ist Super Sanita; 1993 Sep; 29(1):131-7. PubMed ID: 8129259
    [Abstract] [Full Text] [Related]

  • 13. Fetal risks of maternal pharmacotherapy: identifying signals.
    Koren G.
    Handb Exp Pharmacol; 2011 Sep; 205():285-94. PubMed ID: 21882117
    [Abstract] [Full Text] [Related]

  • 14. Knowledge transfer and translation: examining how teratogen information is disseminated.
    Shahin I, Einarson A.
    Birth Defects Res A Clin Mol Teratol; 2011 Nov; 91(11):956-61. PubMed ID: 21948595
    [Abstract] [Full Text] [Related]

  • 15. Counseling regarding pregnancy--related drug exposures by family physicians in Ontario.
    Goodwin J, Rieder S, Rieder MJ, Matsui D.
    Can J Clin Pharmacol; 2007 Nov; 14(1):e58-69. PubMed ID: 17314415
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Human teratogens: update 2010.
    Holmes LB.
    Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
    [Abstract] [Full Text] [Related]

  • 19. Drugs in pregnancy. Drugs to avoid.
    Shehata HA, Nelson-Piercy C.
    Best Pract Res Clin Obstet Gynaecol; 2001 Dec; 15(6):971-86. PubMed ID: 11800536
    [Abstract] [Full Text] [Related]

  • 20. [Perinatal drug administration and risks of functional teratogenic defects].
    Benesová O.
    Cas Lek Cesk; 1994 Jan 31; 133(3):67-70. PubMed ID: 8137374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.